
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7105498/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature Immunology, 2020, 21, 1336-1345.	14.5	1,066
2	Immune control of HIV-1 after early treatment of acute infection. Nature, 2000, 407, 523-526.	27.8	939
3	CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nature Medicine, 2007, 13, 46-53.	30.7	910
4	Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature, 2004, 432, 769-775.	27.8	784
5	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021, 184, 4220-4236.e13.	28.9	630
6	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell, 2022, 185, 2422-2433.e13.	28.9	532
7	Evolution and transmission of stable CTL escape mutations in HIV infection. Nature, 2001, 412, 334-338.	27.8	523
8	HIV and SIV CTL escape: implications for vaccine design. Nature Reviews Immunology, 2004, 4, 630-640.	22.7	467
9	Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1. Journal of Virology, 2006, 80, 3617-3623.	3.4	408
10	Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nature Reviews Immunology, 2008, 8, 619-630.	22.7	408
11	Adaptation of HIV-1 to human leukocyte antigen class I. Nature, 2009, 458, 641-645.	27.8	408
12	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	12.6	352
13	HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature, 2002, 420, 434-439.	27.8	321
14	Escape from the Dominant HLA-B27-Restricted Cytotoxic T-Lymphocyte Response in Gag Is Associated with a Dramatic Reduction in Human Immunodeficiency Virus Type 1 Replication. Journal of Virology, 2007, 81, 12382-12393.	3.4	299
15	HIV and HLA Class I: An Evolving Relationship. Immunity, 2012, 37, 426-440.	14.3	268
16	Immune Selection for Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1 Infection. Journal of Experimental Medicine, 2004, 199, 905-915.	8.5	266
17	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 2021, 184, 5699-5714.e11.	28.9	262
18	Sex Differences in Pediatric Infectious Diseases. Journal of Infectious Diseases, 2014, 209, S120-S126.	4.0	247

#	Article	IF	CITATIONS
19	Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity, 2015, 43, 591-604.	14.3	234
20	Selection bias at the heterosexual HIV-1 transmission bottleneck. Science, 2014, 345, 1254031.	12.6	225
21	Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. Journal of Experimental Medicine, 2005, 201, 891-902.	8.5	220
22	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nature Immunology, 2006, 7, 173-178.	14.5	209
23	Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. Journal of Experimental Medicine, 2008, 205, 1009-1017.	8.5	203
24	Compensatory Mutation Partially Restores Fitness and Delays Reversion of Escape Mutation within the Immunodominant HLA-B*5703-Restricted Gag Epitope in Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2007, 81, 8346-8351.	3.4	197
25	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	4.7	190
26	IVA: accurate <i>de novo</i> assembly of RNA virus genomes. Bioinformatics, 2015, 31, 2374-2376.	4.1	179
27	Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703–positive individuals and their transmission recipients. Journal of Experimental Medicine, 2009, 206, 909-921.	8.5	165
28	The impact of differential antiviral immunity in children and adults. Nature Reviews Immunology, 2012, 12, 636-648.	22.7	157
29	Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point. Journal of Virology, 2008, 82, 8548-8559.	3.4	152
30	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5061.	12.8	150
31	Additive Contribution of HLA Class I Alleles in the Immune Control of HIV-1 Infection. Journal of Virology, 2010, 84, 9879-9888.	3.4	148
32	Control of Human Immunodeficiency Virus Type 1 Is Associated with HLA-B*13 and Targeting of Multiple Gag-Specific CD8 + T-Cell Epitopes. Journal of Virology, 2007, 81, 3667-3672.	3.4	138
33	Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa. Journal of Clinical Virology, 2014, 61, 20-33.	3.1	138
34	Elevated <i>HLA-A</i> expression impairs HIV control through inhibition of NKG2A-expressing cells. Science, 2018, 359, 86-90.	12.6	135
35	Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. Immunity, 2016, 44, 391-405.	14.3	125
36	Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Science Translational Medicine, 2016, 8, 358ra125.	12.4	121

#	Article	IF	CITATIONS
37	Differential Narrow Focusing of Immunodominant Human Immunodeficiency Virus Gag-Specific Cytotoxic T-Lymphocyte Responses in Infected African and Caucasoid Adults and Children. Journal of Virology, 2000, 74, 5679-5690.	3.4	117
38	Phylogenetic Dependency Networks: Inferring Patterns of CTL Escape and Codon Covariation in HIV-1 Gag. PLoS Computational Biology, 2008, 4, e1000225.	3.2	116
39	Widespread Impact of HLA Restriction on Immune Control and Escape Pathways of HIV-1. Journal of Virology, 2012, 86, 5230-5243.	3.4	114
40	HIV-1 Viral Escape in Infancy Followed by Emergence of a Variant-Specific CTL Response. Journal of Immunology, 2005, 174, 7524-7530.	0.8	109
41	International perspectives, progress, and future challenges of paediatric HIV infection. Lancet, The, 2007, 370, 68-80.	13.7	109
42	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 2022, 185, 2116-2131.e18.	28.9	105
43	Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunological Reviews, 1997, 159, 17-29.	6.0	103
44	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	12.8	102
45	Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. Frontiers in Microbiology, 2015, 6, 1016.	3.5	101
46	High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. Aids, 2007, 21, 1253-1261.	2.2	91
47	Gag-Protease-Mediated Replication Capacity in HIV-1 Subtype C Chronic Infection: Associations with HLA Type and Clinical Parameters. Journal of Virology, 2010, 84, 10820-10831.	3.4	87
48	Impact of pre-adapted HIV transmission. Nature Medicine, 2016, 22, 606-613.	30.7	87
49	Rapid Definition of Five Novel HLA-Aâ^—3002-Restricted Human Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Epitopes by Elispot and Intracellular Cytokine Staining Assays. Journal of Virology, 2001, 75, 1339-1347.	3.4	86
50	Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5393-400.	7.1	85
51	Efficacious Early Antiviral Activity of HIV Gag- and Pol-Specific HLA-B*2705-Restricted CD8 + T Cells. Journal of Virology, 2010, 84, 10543-10557.	3.4	84
52	Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. Aids, 2008, 22, 1333-1343.	2.2	83
53	Differential Selection Pressure Exerted on HIV by CTL Targeting Identical Epitopes but Restricted by Distinct HLA Alleles from the Same HLA Supertype. Journal of Immunology, 2006, 177, 4699-4708.	0.8	79
54	Human Immunodeficiency Virus-Specific CD8 ⁺ T-Cell Activity Is Detectable from Birth in the Majority of In Utero-Infected Infants. Journal of Virology, 2007, 81, 12775-12784.	3.4	67

#	Article	IF	CITATIONS
55	HLA-B*57 Micropolymorphism Shapes HLA Allele-Specific Epitope Immunogenicity, Selection Pressure, and HIV Immune Control. Journal of Virology, 2012, 86, 919-929.	3.4	66
56	HIV control: Is getting there the same as staying there?. PLoS Pathogens, 2018, 14, e1007222.	4.7	65
57	Discordant Impact of HLA on Viral Replicative Capacity and Disease Progression in Pediatric and Adult HIV Infection. PLoS Pathogens, 2015, 11, e1004954.	4.7	64
58	HLArestrictor—a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics, 2011, 63, 43-55.	2.4	63
59	Impact of HLA-B*81-Associated Mutations in HIV-1 Gag on Viral Replication Capacity. Journal of Virology, 2012, 86, 3193-3199.	3.4	57
60	Progression to AIDS in South Africa Is Associated with both Reverting and Compensatory Viral Mutations. PLoS ONE, 2011, 6, e19018.	2.5	57
61	Functional Consequences of Human Immunodeficiency Virus Escape from an HLA-B*13-Restricted CD8+ T-Cell Epitope in p1 Gag Protein. Journal of Virology, 2009, 83, 1018-1025.	3.4	54
62	Role of HLA Adaptation in HIV Evolution. Frontiers in Immunology, 2015, 6, 665.	4.8	52
63	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Cell Host and Microbe, 2022, 30, 53-68.e12.	11.0	52
64	HLA-B57-Restricted Cytotoxic T-Lymphocyte Activity in a Single Infected Subject toward Two Optimal Epitopes, One of Which Is Entirely Contained within the Other. Journal of Virology, 2000, 74, 5291-5299.	3.4	51
65	Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. Aids, 2017, 31, 477-484.	2.2	51
66	HLA tapasin independence: broader peptide repertoire and HIV control. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28232-28238.	7.1	51
67	Impact of HLA in Mother and Child on Disease Progression of Pediatric Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2009, 83, 10234-10244.	3.4	50
68	HLA-A*7401–Mediated Control of HIV Viremia Is Independent of Its Linkage Disequilibrium with HLA-B*5703. Journal of Immunology, 2011, 186, 5675-5686.	0.8	49
69	Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope. Journal of Virology, 2012, 86, 12643-12654.	3.4	49
70	Prevalence and Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana. PLoS ONE, 2015, 10, e0134037.	2.5	49
71	HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. Journal of Virology, 2018, 92, .	3.4	47
72	Long-Term Control of HIV-1 in Hemophiliacs Carrying Slow-Progressing Allele HLA-B*5101. Journal of Virology, 2010, 84, 7151-7160.	3.4	42

#	Article	IF	CITATIONS
73	Efficient Processing of the Immunodominant, HLA-A*0201-Restricted Human Immunodeficiency Virus Type 1 Cytotoxic T-Lymphocyte Epitope despite Multiple Variations in the Epitope Flanking Sequences. Journal of Virology, 1999, 73, 10191-10198.	3.4	42
74	HIV Control through a Single Nucleotide on the HLA-B Locus. Journal of Virology, 2012, 86, 11493-11500.	3.4	41
75	HLA Footprints on Human Immunodeficiency Virus Type 1 Are Associated with Interclade Polymorphisms and Intraclade Phylogenetic Clustering. Journal of Virology, 2009, 83, 4605-4615.	3.4	40
76	Immune activation and paediatric HIV-1 disease outcome. Current Opinion in HIV and AIDS, 2016, 11, 146-155.	3.8	39
77	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathogens, 2021, 17, e1009804.	4.7	39
78	Unique Acquisition of Cytotoxic T-Lymphocyte Escape Mutants in Infant Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2005, 79, 12100-12105.	3.4	38
79	'Unleashed' natural killers hinder HIV. Nature Genetics, 2007, 39, 708-710.	21.4	35
80	A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape. Retrovirology, 2015, 12, 20.	2.0	35
81	Malnutrition in HIV-Infected Children Is an Indicator of Severe Disease with an Impaired Response to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2018, 34, 46-55.	1.1	35
82	Replicative Capacity of Human Immunodeficiency Virus Type 1 Transmitted from Mother to Child Is Associated with Pediatric Disease Progression Rate. Journal of Virology, 2010, 84, 492-502.	3.4	33
83	Reconstitution of Virus-Specific CD4 Proliferative Responses in Pediatric HIV-1 Infection. Journal of Immunology, 2003, 171, 6968-6975.	0.8	31
84	Role of HIV-specific CD8+ T cells in pediatric HIV cure strategies after widespread early viral escape. Journal of Experimental Medicine, 2017, 214, 3239-3261.	8.5	31
85	Combined structural and immunological refinement of HIV-1 HLA-B8-restricted cytotoxic T lymphocyte epitopes. European Journal of Immunology, 1997, 27, 1515-1521.	2.9	30
86	Reduced Expression of Siglec-7, NKG2A, and CD57 on Terminally Differentiated CD56 ^{â^²} CD16 ⁺ Natural Killer Cell Subset Is Associated with Natural Killer Cell Dysfunction in Chronic HIV-1 Clade C Infection. AIDS Research and Human Retroviruses, 2017, 33, 1205-1213.	1.1	29
87	High-Frequency, Functional HIV-Specific T-Follicular Helper and Regulatory Cells Are Present Within Germinal Centers in Children but Not Adults. Frontiers in Immunology, 2018, 9, 1975.	4.8	29
88	CD8 ⁺ T Cell Breadth and <i>Ex Vivo</i> Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles. Journal of Virology, 2016, 90, 6818-6831.	3.4	27
89	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	5.0	26
90	Major TCR Repertoire Perturbation by Immunodominant HLA-B*44:03-Restricted CMV-Specific T Cells. Frontiers in Immunology, 2018, 9, 2539.	4.8	25

6

#	Article	IF	CITATIONS
91	Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations. PLoS ONE, 2017, 12, e0189612.	2.5	24
92	HIGH-FREQUENCY failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal NON-ADHERENCE. EClinicalMedicine, 2020, 22, 100344.	7.1	23
93	Strong sex bias in elite control of paediatric HIV infection. Aids, 2019, 33, 67-75.	2.2	22
94	HLA-B*35. Aids, 2014, 28, 959-967.	2.2	21
95	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications, 2022, 13, 1251.	12.8	20
96	HIV Subtype Influences HLA-B*07:02-Associated HIV Disease Outcome. AIDS Research and Human Retroviruses, 2014, 30, 468-475.	1.1	19
97	Sex Differences in Antiretroviral Therapy Initiation in Pediatric HIV Infection. PLoS ONE, 2015, 10, e0131591.	2.5	19
98	Motif Inference Reveals Optimal CTL Epitopes Presented by HLA Class I Alleles Highly Prevalent in Southern Africa. Journal of Immunology, 2006, 176, 4699-4705.	0.8	17
99	Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load. Aids, 2014, 28, 2007-2021.	2.2	17
100	Impact of HLA Selection Pressure on HIV Fitness at a Population Level in Mexico and Barbados. Journal of Virology, 2014, 88, 10392-10398.	3.4	15
101	Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection. Nature Communications, 2020, 11, 1767.	12.8	15
102	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. Journal of Virology, 2017, 91, .	3.4	14
103	Differential Immunodominance Hierarchy of CD8 ⁺ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	3.4	14
104	Rapid Characterization of HIV Clade Câ€Specific Cytotoxic T Lymphocyte Responses in Infected African Children and Adults. Annals of the New York Academy of Sciences, 2000, 918, 330-345.	3.8	13
105	Impact of HLA-B*35 subtype differences on HIV disease outcome in Mexico. Aids, 2014, 28, 1687-1690.	2.2	13
106	Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity. Journal of Virology, 2017, 91, .	3.4	13
107	Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient. Retrovirology, 2018, 15, 7.	2.0	13
108	Increased Regulatory T-Cell Activity and Enhanced T-Cell Homeostatic Signaling in Slow Progressing HIV-infected Children. Frontiers in Immunology, 2019, 10, 213.	4.8	13

#	Article	IF	CITATIONS
109	The impact of antiretroviral therapy on population-level virulence evolution of HIV-1. Journal of the Royal Society Interface, 2015, 12, 20150888.	3.4	12
110	An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults. PLoS Pathogens, 2021, 17, e1010090.	4.7	12
111	Disease progression despite protective HLA expression in an HIV-infected transmission pair. Retrovirology, 2015, 12, 55.	2.0	11
112	Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8 + T Cells. Journal of Virology, 2016, 90, 8552-8562.	3.4	11
113	Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors. Aids, 2022, 36, 95-105.	2.2	11
114	Identification of Conserved Subdominant HIV Type 1 CD8 ⁺ T Cell Epitopes Restricted Within Common HLA Supertypes for Therapeutic HIV Type 1 Vaccines. AIDS Research and Human Retroviruses, 2012, 28, 1434-1443.	1.1	10
115	Differential Pathogen-Specific Immune Reconstitution in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Children. Journal of Infectious Diseases, 2019, 219, 1407-1417.	4.0	10
116	Large-scale inference of correlation among mixed-type biological traits with phylogenetic multivariate probit models. Annals of Applied Statistics, 2021, 15, .	1.1	10
117	HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults. Journal of Infectious Diseases, 2016, 213, 1248-1252.	4.0	9
118	Recovery of effective HIV-specific CD4+ T-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia. Aids, 2018, 32, 1413-1422.	2.2	9
119	Innate Lymphoid Cell Activation and Sustained Depletion in Blood and Tissue of Children Infected with HIV from Birth Despite Antiretroviral Therapy. Cell Reports, 2020, 32, 108153.	6.4	9
120	Early Initiation of Antiretroviral Therapy Following In Utero HIV Infection Is Associated With Low Viral Reservoirs but Other Factors Determine Viral Rebound. Journal of Infectious Diseases, 2021, 224, 1925-1934.	4.0	9
121	HLA-Specific Intracellular Epitope Processing Shapes an Immunodominance Pattern for HLA-B*57 That Is Distinct from HLA-B*58:01. Journal of Virology, 2013, 87, 10889-10894.	3.4	8
122	Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Research, 0, 7, 32.	1.8	8
123	Detection of HIV Type 1 Gag-Specific CD4 ⁺ T Cell Responses in Acutely Infected Infants. AIDS Research and Human Retroviruses, 2008, 24, 265-270.	1.1	7
124	HLA-A*68. Aids, 2013, 27, 1717-1723.	2.2	7
125	Impact of HLA Allele-KIR Pairs on HIV Clinical Outcome in South Africa. Journal of Infectious Diseases, 2019, 219, 1456-1463.	4.0	7
126	Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection. MSphere, 2020, 5, .	2.9	7

#	Article	IF	CITATIONS
127	Lower Viral Loads and Slower CD4 ⁺ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02. Journal of Infectious Diseases, 2016, 214, 379-389.	4.0	6
128	Mapping the drivers of within-host pathogen evolution using massive data sets. Nature Communications, 2019, 10, 3017.	12.8	6
129	Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children. Frontiers in Immunology, 2019, 10, 1497.	4.8	5
130	Impact of HLA-B*52:01-Driven Escape Mutations on Viral Replicative Capacity. Journal of Virology, 2020, 94, .	3.4	5
131	Subdominant Gag-specific anti-HIV efficacy in an HLA-B*57-positive elite controller. Aids, 2016, 30, 972-974.	2.2	4
132	Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Research, 0, 7, 32.	1.8	4
133	A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells. Journal of Immunological Methods, 2022, 504, 113263.	1.4	4
134	Cytotoxic T lymphocytes and viral adaptation in HIV infection. Current Opinion in HIV and AIDS, 2006, 1, 241-248.	3.8	3
135	Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV. Journal of Virology, 2022, 96, JVI0153521.	3.4	3
136	Non-Immunogenicity of Overlapping Gag Peptides Pulsed on Autologous Cells after Vaccination of HIV Infected Individuals. PLoS ONE, 2013, 8, e74389.	2.5	2
137	Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities. PLoS ONE, 2017, 12, e0184496.	2.5	2
138	Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. Aids, 2021, 35, 1597-1604.	2.2	2
139	HIV-1 evades a Gag mutation that abrogates killer cell immunoglobulin-like receptor binding and disinhibits natural killer cells in infected individuals with KIR2DL2+/HLA-Câ^—03:04+ genotype. Aids, 2021, 35, 151-154.	2.2	2
140	Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Research, 0, 7, 32.	1.8	2
141	A Randomised, Placebo-Controlled, First-In-Human Study of a Novel Clade C Therapeutic Peptide Vaccine Administered Ex Vivo to Autologous White Blood Cells in HIV Infected Individuals. PLoS ONE, 2013, 8, e73765.	2.5	1
142	Approaches Towards Avoiding Lifelong Antiretroviral Therapy in Paediatric HIV Infection. Advances in Experimental Medicine and Biology, 2012, 719, 25-37.	1.6	1
143	Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era. Frontiers in Immunology, 2022, 13, .	4.8	1
144	Reply to Eisenhut. Journal of Infectious Diseases, 2015, 211, 664-665.	4.0	0

#	Article	IF	CITATIONS
145	Reply to Jefferys: Declining HIV virulence. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2119-E2119.	7.1	0
146	Next-generation point-of-care testing in pediatric human immunodeficiency virus infection facilitates diagnosis and monitoring of treatment. Medicine (United States), 2022, 101, e29228.	1.0	0